Morecki S, Nabet C, Ackerstein A, Schlesinger M, Slavin S
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Bone Marrow Transplant. 1991 Apr;7(4):269-73.
The effect of immunocompetent lymphocyte depletion on precursors and effector cells of IL2 activated non-MHC restricted cytotoxic cells (LAK) generated from bone marrow (BM) or peripheral blood was investigated. Lymphocyte depletion was carried out by using Campath-1, a monoclonal rat anti-human lymphocyte antibody recognizing CDW52, that binds human complement and is used routinely in clinical bone marrow transplantation (BMT). The results indicate that LAK precursors derived from BM cells are sensitive to Campath-1 treatment, while a variable degree of sensitivity was demonstrated in LAK precursor cells derived from peripheral blood. In contrast, effector LAK cells generated in vitro were shown to be resistant to treatment with Campath-1 and complement. We hypothesize that if indeed IL2-dependent non-MHC restricted cytotoxic cells play a role in vivo in the immediate post-BMT period, a T lymphocyte depletion procedure such as the Campath-1 may have the capacity to reduce, at least temporarily, the graft-versus leukemia effects mediated by such anti-tumor effector mechanisms.
研究了免疫活性淋巴细胞耗竭对从骨髓(BM)或外周血产生的IL2激活的非MHC限制性细胞毒性细胞(LAK)的前体细胞和效应细胞的影响。使用Campath-1进行淋巴细胞耗竭,Campath-1是一种识别CDW52的大鼠抗人淋巴细胞单克隆抗体,它能结合人补体,常用于临床骨髓移植(BMT)。结果表明,源自BM细胞的LAK前体细胞对Campath-1治疗敏感,而源自外周血的LAK前体细胞表现出不同程度的敏感性。相比之下,体外产生的效应性LAK细胞对Campath-1和补体治疗具有抗性。我们推测,如果IL2依赖性非MHC限制性细胞毒性细胞确实在BMT后即刻的体内发挥作用,那么诸如Campath-1之类的T淋巴细胞耗竭程序可能至少在短期内有能力降低此类抗肿瘤效应机制介导的移植物抗白血病效应。